FDA Clears At-Home Starting Dose for Eisai's Alzheimer's Drug Leqembi
Eisai and Biogen can now sell a weekly, 15-second self-injection as the starting treatment for early Alzheimer's disease, not just the maintenance dose already approved last year.
Company1 article
Companies
Eisai Co., Ltd.
Latest Tokyo Brief coverage on Eisai Co., Ltd., tracking filings, financial news, and market signals from Japan.
- Code
- 4523
- Exchange
- TSE
- Coverage
- 1 article
Latest coverage
TSE:4523